Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8011 to 8025 of 8904 results

  1. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

    We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  2. Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

    This guidance has been updated and replaced by NICE technology appraisal guidance 629.

    Withdrawn guidance

  3. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (TA48)

    This guidance has been updated and replaced by NICE guideline NG107 

    Withdrawn guidance

  4. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Withdrawn guidance

  5. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    This guidance has been updated and replaced by NICE technology appraisal guidance 713.

    Withdrawn guidance

  6. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

    Withdrawn guidance

  7. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Withdrawn guidance

  8. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Withdrawn guidance

  9. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Withdrawn guidance

  10. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

    Withdrawn guidance

  11. IQoro for stroke-related dysphagia (MIB175)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  12. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

    This advice has been updated and replaced by NICE healthtech guidance 553.

    Withdrawn advice

  13. Curos disinfecting cap for needleless connectors (MIB143)

    This advice has been updated and replaced by NICE medical technologies guidance 44.

    Withdrawn advice

  14. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE healthtech guidance 620.

    Withdrawn advice

  15. Alpha-Stim AID for anxiety (MIB193)

    This advice has been updated and replaced by NICE healthtech guidance 570.

    Withdrawn advice